CFTR Modulators

Trikafta has done wonders for my health but not my waistline. I was relieved to find out, however, that I wasn’t alone in my concern about my sudden weight gain and that bringing the topic up to my care team didn’t mean that I wasn’t grateful for all Trikafta has done for me.

The imagination can run wild thinking of all the possible scenarios that could happen after trying the new triple-combination modulator, Trikafta™. Managing expectations -- while allowing yourself to hope -- is how I choose to approach my wait for the new drug.

Drug makers are edging closer to new treatments for cystic fibrosis that could stop the destructive impact of the disease, says an article in The Wall Street Journal today.

The Wall Street Journal reports that the CF Foundation played a major role in the funding of a new potential medicine – Kalydeco (VX 770) – and is a pioneer in driving drug development for rare diseases.

The CF Foundation is focused on bringing forward new therapies to help people with CF enjoy the best health and quality of life. Following the approval of the new CF drug Orkambi, we sat down with Dr. Mike Boyle, our new vice president of therapeutics development, to learn more about the future of clinical research and what’s most exciting.

Vertex Pharmaceuticals Inc. announced today that it has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for approval of the combination of ivacaftor (Kalydeco™) and lumacaftor.